Steady states and dynamics of urokinase-mediated plasmin activation in silico and in vitro.

[1]  Jacob K. White,et al.  Cell-delivery therapeutics for liver regeneration. , 2010, Advanced drug delivery reviews.

[2]  U. Matte,et al.  Plasmin-mediated Proteolysis Is Required for Hepatocyte Growth Factor Activation during Liver Repair* , 2009, Journal of Biological Chemistry.

[3]  Valérie Ferreira,et al.  VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. , 2008, European journal of cancer.

[4]  Tingzhe Sun,et al.  Two Independent Positive Feedbacks and Bistability in the Bcl-2 Apoptotic Switch , 2008, PloS one.

[5]  Frank Allgöwer,et al.  Steady state and (bi-) stability evaluation of simple protease signalling networks , 2007, Biosyst..

[6]  Wei Zhang,et al.  Robustness analysis identifies the plausible model of the Bcl‐2 apoptotic switch , 2007, FEBS letters.

[7]  John J. Tyson,et al.  Irreversible cell-cycle transitions are due to systems-level feedback , 2007, Nature Cell Biology.

[8]  Rui Wang,et al.  Modeling of the role of a Bax-activation switch in the mitochondrial apoptosis decision. , 2007, Biophysical journal.

[9]  James E. Ferrell,et al.  Substrate Competition as a Source of Ultrasensitivity in the Inactivation of Wee1 , 2007, Cell.

[10]  S. Martin,et al.  The CASBAH: a searchable database of caspase substrates , 2007, Cell Death and Differentiation.

[11]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[12]  Nils Blüthgen,et al.  Mathematical Modeling Identifies Inhibitors of Apoptosis as Mediators of Positive Feedback and Bistability , 2006, PLoS Comput. Biol..

[13]  E. Lakatta,et al.  Matrix Metalloproteinase 2 Activation of Transforming Growth Factor-&bgr;1 (TGF-&bgr;1) and TGF-&bgr;1–Type II Receptor Signaling Within the Aged Arterial Wall , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. Quax,et al.  Pericellular proteases in angiogenesis and vasculogenesis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Angeli,et al.  New analysis technique for multistability detection. , 2006, Systems biology.

[16]  G B Ermentrout,et al.  Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. , 2006, Biophysical journal.

[17]  F. Allgöwer,et al.  Bistability Analyses of a Caspase Activation Model for Receptor-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[18]  M. Schenone,et al.  The blood coagulation cascade , 2004, Current opinion in hematology.

[19]  B. Kholodenko,et al.  Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades , 2004, The Journal of cell biology.

[20]  T. Tuan,et al.  Plasminogen activator/plasmin system: A major player in wound healing? , 2003, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[21]  J. Rakic,et al.  Role of plasminogen activator-plasmin system in tumor angiogenesis , 2003, Cellular and Molecular Life Sciences CMLS.

[22]  J. Ferrell.  Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. , 2002, Current opinion in cell biology.

[23]  I. Iwan-Ziętek,et al.  Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[24]  J. Ferrell,et al.  Bistability in the JNK cascade , 2001, Current Biology.

[25]  H. Lijnen.  Plasmin and Matrix Metalloproteinases in Vascular Remodeling , 2001, Thrombosis and Haemostasis.

[26]  H. Stennicke,et al.  Catalytic properties of the caspases , 1999, Cell Death and Differentiation.

[27]  E. Angles-cano,et al.  Evidence that Modifications of Lp(a) In Vivo Inhibit Plasmin Formation on Fibrin , 1999, Thrombosis and Haemostasis.

[28]  J. Sipley,et al.  Activation of ProMMP‐9 by a Plasmin/MMP‐3 Cascade in a Tumor Cell Model: Regulation by Tissue Inhibitors of Metalloproteinases , 1999, Annals of the New York Academy of Sciences.

[29]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[30]  U. Bhalla,et al.  Emergent properties of networks of biological signaling pathways. , 1999, Science.

[31]  Chi-Ying F. Huang,et al.  Ultrasensitivity in the mitogen-activated protein kinase cascade. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Thompson,et al.  Plasmin, fibrin degradation and angiogenesis , 1996, Nature Medicine.

[33]  P. Carmeliet,et al.  Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals. , 1995, Trends in cardiovascular medicine.

[34]  G. Leipnitz,et al.  Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. , 1991, Thrombosis research.

[35]  S. L. Gonias,et al.  Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by α2-antiplasmin, α2-macroglobulin, and antithrombin III in the presence of heparin1 , 1990 .

[36]  Y. Takada,et al.  The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. , 1990, Thrombosis research.

[37]  H. Moses,et al.  Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin , 1990, The Journal of cell biology.

[38]  D. Collen,et al.  The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. , 1989, Blood.

[39]  B. Binder,et al.  Increased Plasma Levels of Urokinase-Type Plasminogen Activator With Endometrial and Cervical Cancer , 1988, Obstetrics and gynecology.

[40]  M. Scully,et al.  Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. , 1987, The Journal of biological chemistry.

[41]  M. Hoylaerts,et al.  Activation of plasminogen by pro-urokinase. II. Kinetics. , 1986, The Journal of biological chemistry.

[42]  P. McKee,et al.  The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity. , 1983, The Journal of biological chemistry.

[43]  G. Reinhart,et al.  Rat liver phosphofructokinase: kinetic activity under near-physiological conditions. , 1980, Biochemistry.

[44]  G. Tytgat,et al.  Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. , 1972, The Journal of clinical investigation.

[45]  Sangdun Choi,et al.  Introduction To Systems Biology , 2010 .

[46]  V. Kähäri,et al.  Proteinases in cutaneous wound healing , 2008, Cellular and Molecular Life Sciences.

[47]  Nils Blüthgen,et al.  Mechanisms Generating Ultrasensitivity, Bistability, and Oscillations in Signal Transduction , 2007 .

[48]  E. Crivellato,et al.  The history of the angiogenic switch concept , 2007, Leukemia.

[49]  V. Gurewich,et al.  Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). , 1987, Blood.

[50]  D. Collen,et al.  Activation of Plasminogen by Pro-urokinase , 1986 .

[51]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.

[52]  D. Collen,et al.  Interaction of Plasminogen Activators and Inhibitors with Plasminogen and Fibrin , 1982, Seminars in thrombosis and hemostasis.

[53]  P. Wolf,et al.  The demonstration of urokinase antigen in whole blood. , 1979, Thrombosis research.

[54]  K. Robbins,et al.  [10] Human plasminogen and plasmin , 1970 .

[55]  S. Lowen.  The Biophysical Journal , 1960, Nature.